Episode 184 - May 29, 2026

What It Covers

Biotech Hangout Episode 184 covers the 2026 IPO market health with 11 filings by May, Ginkgo Bioworks CEO Jason Kelly's national security argument against offshoring biotechnology to China, Eli Lilly's three vaccine acquisitions totaling $3.8B, and key ASCO oncology data previews including Revolution Medicines' pancreatic cancer results.

Key Questions Answered

• •Biotech IPO benchmark: Eleven biotech IPOs filed by end of May 2026 already matches or exceeds all of 2025's total. Investor sentiment index reached 120 among finance and investment stakeholders in Q2 2026, up from 78 in Q4 2025. Later-stage clinical assets with phase 2b data characterize this cycle, distinguishing it from frothier preclinical-heavy prior waves.
• •China offshoring risk framework: Massachusetts lost 1,100 biotech R&D jobs in 2024, the first such decline MassBio has recorded, with one-third of lab space now vacant. Jason Kelly frames this as structural offshoring of genetic engineering capability, not cyclical decline. Investors and biotechs should monitor whether discovery-stage science, not just manufacturing, is migrating to China.
• •Alternative financing structure: Apogee Biosciences secured up to $1.3B from Blackstone Life Sciences concurrent with positive phase 2 atopic dermatitis data, bypassing traditional equity follow-on raises entirely. The deal splits into $800M synthetic royalty financing and $500M senior debt. Biotechs with late-stage assets should evaluate royalty-based non-dilutive structures as a capital-raising alternative to bank-led offerings.
• •RAS inhibitor efficacy bar: Revolution Medicines' daraxonrasib achieved 13.2 months median overall survival in second-line pancreatic cancer versus 6.7 months for standard chemotherapy in the phase 3 RESOLUTE-302 study. Full data present at ASCO 2026 plenary. Companies developing follow-on pan-RAS inhibitors, including Rasca and Verastem, now face this doubling of survival as the competitive efficacy threshold to clear.
• •Myostatin combination strategy for obesity: Biohaven's myostatin antibody teldafrecapap alpha, combined with semaglutide, targets the body composition problem of GLP-1 therapies, where significant muscle mass loss accompanies fat loss. Phase 2 data are forthcoming. Investors tracking obesity pipeline should assess combination approaches preserving lean mass, particularly as Lilly's bimagramab showed tolerability issues and appears to have stalled development.